Allakos Inc. (NASDAQ:ALLK – Get Rating) shares gapped down before the market opened on Wednesday . The stock had previously closed at $7.43, but opened at $7.26. Allakos shares last traded at $7.36, with a volume of 1,101 shares traded.
Allakos Stock Up 3.6 %
The company has a market capitalization of $657.77 million, a P/E ratio of -1.14 and a beta of 0.51. The company’s fifty day moving average price is $7.49 and its 200 day moving average price is $5.63.
Allakos (NASDAQ:ALLK – Get Rating) last posted its quarterly earnings results on Monday, November 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.25. Research analysts predict that Allakos Inc. will post -5.18 earnings per share for the current fiscal year.
Institutional Trading of Allakos
Allakos Company Profile
Allakos Inc, a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.
- Get a free copy of the StockNews.com research report on Allakos (ALLK)
- Deere, Catepillar, PACCAR, Machinery Stocks You Need to Know
- 3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
- Optimism About Global Demand For Metals Boosts BHP, Other Miners
- Exxon Mobil Expects Earnings and Cash Flow to Grow
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.